SeekingAlpha · Aug 10, 2026
Puma Biotechnology, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-10. The following slide deck was published by Puma Biotechnology, Inc.
PB
NASDAQ · PBYI
Puma Biotechnology, Inc.
Healthcare · Biotechnology
$8.71
Down-$0.19 (-2.13%)
Updated Aug 14, 2026, 2:09 AM
SID Score
7.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 288.74M
- P/E ratio
- 7.8
- Dividend yield
- 0.00%
- 52-week range
- $5.85 – $9.40
- Volume
- 263.05K
- Avg. volume
- 523.37K
Price performance
PBYI price history
1M range · 0 trading sessions · Daily adjusted prices
PBYI does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest PBYI news
The latest Smart Investors Daily articles mentioning PBYI.
Stock researchCompany · Overview
PBYI research
Overview
Company profile and research snapshot.
Company profile
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | TD Cowen | Hold | — |
| Feb 28, 2025 | HC Wainwright & Co. | Buy | — |
| Dec 23, 2024 | HC Wainwright & Co. | Buy | — |
| Nov 20, 2024 | HC Wainwright & Co. | Buy | — |
| Nov 8, 2024 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 7, 2026
TD Cowen Maintains Hold on Puma Biotechnology, Raises Price Target to $6
TD Cowen analyst Marc Frahm maintains Puma Biotechnology (NASDAQ:PBYI) with a Hold and raises the price target from $5 to $6.
SeekingAlpha · Aug 7, 2026
Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript
Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsMariann Ohanesian - Senior Director of Investor...
ChartMill · Aug 7, 2026
Puma Biotechnology (NASDAQ:PBYI) Beats Q2 Estimates, but Soft Q3 Guidance Tempers Reaction
Puma Biotechnology (PBYI) Q2 beats estimates, raises full-year revenue guidance, but softer Q3 outlook keeps market reaction muted.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
